No Data
No Data
BioRestorative Therapies Clarifies Disclosure Regulations Impact
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced its
BioRestorative Reports Positive Trend in Back Pain Study
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting
MELVILLE, NY / ACCESSWIRE / February 14, 2024 / BioRestorative Therapies (NASDAQ:BRTX) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease
Biorestorative Therapies(BRTX.US) 10% Shareholder Buys US$206.02K in Common Stocks
$Biorestorative Therapies(BRTX.US)$ 10% Shareholder Broadrick Dale purchased 160K shares of Common Stocks on Feb 8, 9, 2024 at an average price of $1.29 for a total value of $206.02K.Source: Announcem
Porch Group And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed lower by more than 50 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders
No Data